Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.50 |
| ▸ | KDM6B | O15054 | 2/20 | 0.50 |
| ▸ | KDM5C | P41229 | 2/20 | 0.50 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.50 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.50 |
| ▸ | KDM3A | Q9Y4C1 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | AR | P10275 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | TET3 | O43151 | 1/20 | 0.47 |
| ▸ | KDM4A | O75164 | 1/20 | 0.47 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.47 |
| ▸ | KDM5A | P29375 | 1/20 | 0.47 |
| ▸ | ASPH | Q12797 | 1/20 | 0.47 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.47 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.47 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.47 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.47 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30236802 | 1.00 | KDM4E (0.50) | KDM4EKDM6BKDM5CKDM4CKDM2A | |
| SCHEMBL70350 | 0.89 | KDM4E (0.62) | KDM4EKDM6BKDM5CKDM4CKDM2A | |
| SCHEMBL30065796 | 0.89 | KDM4E (0.62) | KDM4EKDM6BKDM5CKDM4CKDM2A | |
| SCHEMBL1759313 | 0.86 | KDM4E (0.58) | KDM4EKDM6BKDM5CKDM4CKDM2A | |
| SCHEMBL2716237 | 0.86 | KDM4E (0.68) | KDM4EKDM6BKDM5CKDM4CKDM2A | |
| SCHEMBL30378954 | 0.86 | KDM4E (0.58) | KDM4EKDM6BKDM5CKDM4CKDM2A | |
| SCHEMBL30745026 | 0.86 | KDM4E (0.68) | KDM4EKDM6BKDM5CKDM4CKDM2A | |
| SCHEMBL29272221 | 0.85 | KDM4E (0.47) | KDM4EKDM6BKDM5CKDM4CKDM2A | |
| SCHEMBL30236724 | 0.85 | KDM4E (0.47) | KDM4EKDM6BKDM5CKDM4CKDM2A | |
| SCHEMBL24572936 | 0.84 | MAP4K4 (0.49) | ALDH1A1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3529247-B1 | HETEROCYCLIC FXR MODULATORS | HEPAGENE THERAPEUTICS HK LTD (HK) | 2021-08-18 | — | — | EP | disclosed |
| US-20190248752-A1 | HETEROCYCLIC FXR MODULATORS | Hepagene Therapeutics (HK) Limited (HK) | 2019-08-15 | — | — | US | disclosed |
| WO-2018075207-A1 | HETEROCYCLIC FXR MODULATORS | HEPAGENE THERAPEUTICS, INC. (VG) | 2018-04-26 | — | — | WO | disclosed |
| CN-101321753-A | Novel imidazo [4,5 -b] pyridine derivatives as inhibitors of glycogen synthase kinase 3 for use in the treatment of dementia and neurodegenerative disorders | ASTRAZENECA AB (SE) | 2008-12-10 | — | — | CN | disclosed |
| US-20080255085-A1 | Novel Imidazo [4,5-b] Pyridine Derivatives as Inhibitors of Glycogen Synthase Kinase 3 for Use in the Treatment of Dementia and Neurodegenerative Disorders | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | disclosed |
| EP-1937680-A2 | NOVEL IMIDAZO [4,5 -B] PYRIDINE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 FOR USE IN THE TREATMENT OF DEMENTIA AND NEURODEGENERATIVE DISORDERS | AstraZeneca AB (SE) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007040438-A2 | NOVEL IMIDAZO [4,5 -B] PYRIDINE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 FOR USE IN THE TREATMENT OF DEMENTIA AND NEURODEGENERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255085-A1 | Novel Imidazo [4,5-b] Pyridine Derivatives as Inhibitors of Glycogen Synthase Kinase 3 for Use in the Treatment of Dementia and Neurodegenerative Disorders | GSK3B, GSK3A, PYGB | KDM4E 923/4885KDM6B 920/4885KDM5C 1345/4885 |
| US-20190248752-A1 | HETEROCYCLIC FXR MODULATORS | NR1H4, FXR1, NR1H2 | KDM4E 4596/4885KDM6B 4528/4885KDM5C 4586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.